Date Published: July 01, 2015
Author(s): Lon S. Schneider.
There are several advantages of an online, open access journal when compared with subscription-based, print journals. These include rapid review, publication within a few weeks of final acceptance, and the ability to post full-color, high-resolution graphics, video clips, and substantial supplemental material, such as protocols, methods, data forms, and programing code. Open access authors hold the copyright to their article, and publication of their articles meet the National Institutes of Health’s and other funders’ requirements for rapid dissemination of research outcomes.
The content for Alzheimer’s & Dementia: Translational Research & Clinical Interventions is guided and informed by the Common Alzheimer’s Disease Research Ontology, Categories C and E, in particular; and the International Alzheimer’s Disease Research Portfolio that aims to capture global Alzheimer research funding as well . These categories include topics focused on the identification and development of therapies for Alzheimer’s disease from early discovery through late stage preclinical development, all stages of clinical testing, interventions, and trials, as well as non-pharmacological primary, secondary, and tertiary interventions, including cognitive training, behavioral, neuropsychological interventions, outcomes, and treatment development (Box 1).Box 1Common Alzheimer’s Disease Research OntologyCategory C. Translational research and clinical interventions1.Drug discovery2.Preclinical therapy developmentPharmacological and non-pharmacological interventions3.Clinical trial design and methods4.Proof of concept and feasibility trials5.Prevention trials6.Treatment trials – cognitionVarious interventions7.Treatment trials – neuropsychiatric, behavioral and psychological comorbidityPharmacological and non-pharmacologicalCategory E. Care, support, and health economics1.Care interventions and quality of life2.Technology assisted care3.Caregiver support4.Cultural values and beliefs5.Economic burden(From: Refolo LM, et al. Alzheimer’s & Dementia. 2012;8:372-5 )
Alzheimer’s & Dementia: Translational Research & Clinical Interventions encourages the submission of studies describing preclinical, translational research with potential for clinical application, research from early human experimentation (experimental medicine), clinical trials, prevention studies, clinical research bioinformatics, systematic reviews, metaanalyses, commentary, and perspectives that have the potential to advance treatment of Alzheimer’s disease pathology, neurodegeneration, and cognitive impairment, and improve patients’ lives. This is research that bridges the laboratory and clinical settings, including molecular characterization, discovery, formulation, prevention, detection, diagnosis and treatment, with the overall goal of improving the clinical care.
The Editor-in-Chief of Alzheimer’s & Dementia: Translational Research & Clinical Interventions, is Dr. Lon S. Schneider. The Senior Associate Editors are Drs. Steven T. DeKosky, Hiroko Dodge, Miia Kivipelto, Simon Lovestone, Rupert McShane, and Mary Sano. Each has made important contributions to translational research, and will provide breadth, depth, experience, and perspective on the journal’s direction.